Once-weekly Sogroya wins FDA approval for pediatric growth hormone deficiency

FDA has approved Sogroya (somapacitan-beco) injection for once-weekly treatment of pediatric patients ages 2.5 years and older with growth failure due to inadequate secretion of endogenous growth hormone (GH). Sogroya, a human GH analog, had earlier been approved only for treating adult patients with GH deficiency.